Nadege Gunn
Gastroenterology · Waco, TXNPI 1902822281
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by Gilead at 24.8% of the total. 2025 is the largest year on record at $487,497, 7.5 times the $64,813 reported in 2019. Among gastroenterology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,089 payments — averaging $856.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$232K
- Madrigal Pharmaceuticals$218K
- Boehringer Ingelheim$145K
- Novo Nordisk$133K
- Ipsen Biopharmaceuticals, Inc$74K
- Boehringer Ingelheim International GmbH$47K
- plus $84K from 36 others
Across 641 payments — averaging $7456.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$936K
- Gilead$706K
- Boehringer Ingelheim International GmbH$512K
- Vertex$494K
- Eli Lilly$479K
- Bausch Health US, LLC$378K
- plus $1.3M from 10 others
What the payments were for
- Consulting fees$285,60031%
- Speaking & faculty fees$471,07950%
- Travel & lodging$145,95816%
- Food & beverage$30,3763%
- Education$770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$933,090 in reported general payments places this provider in the 95th percentile of 1,350 gastroenterology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 16 | $389,951 |
| VemlidyTenofovir Alafenamide | 12 | $17,395 |
| Ursodiol | 29 | $3,286 |
| Spironolactone | 11 | $231 |
| Mycophenolic AcidMycophenolate Sodium | 13 | $181 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa, Vemlidy | $231,863 | $407,34628 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,350 gastroenterology providers in Texas.
Other gastroenterology in Waco
- John FordtranDallas$9.9M
- Michael BrownDallas$5.5M
- Bincy AbrahamHouston$1.6M
- Mazen NoureddinHouston$1.5M
- Stephen PappasHouston$1.4M
- Anish PatelFort Sam Houston$1.3M
- Timothy RitterSouthlake$961K
- Parvez MantryDallas$958K
- Brooks CashHouston$867K
- Mohamed OthmanHouston$777K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.